United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase… bypharmanewsdailyMarch 31, 2019